(secukinumab)

Support from the initial be authorization and appeals	nefits verification through p	Bene	ort from the initial benefits ver fits Verification Only: fits verification without prior a	U	h prior authorization and appeals appeals support
1 Patient Information For patients younger than 18 y	ears of age, please provide	a parent or guardiar	n's phone number.		* = REQUIRED FIELDS
First Name* / / Date of Birth (MM/DD/YYYY)	Last Name* Sex for Clinical	Use: 🗌 Male 🗌 F	Email emale Phone Number* (We'll keep you update		Mobile
Address (No PO Box)*			OK to Leave Voicem		- ·
City I give permission to disclose	State e my personal health info	ZIP* rmation to the follo	Preferred Language wing (optional):	Spanish	
Name				Other:_	
Phone Number ⁺ (We'll keep you	updated through non-market	ng calls/texts [†])	Relationship to Patie		
2 Patient Authorization a I have read and agree to the Pa			,	/	
Patient or Authorized R	epresentative Signature d by an authorized represe	ntative	/ Date (MM/I	/ D/YYYY)	Scan the code to learn more about COSENTYX.
PATIENT SUPPORT CO-PAY I have read and agree to th Offer Terms and Condition Co-pay support payments directly to my provider on the	e \$0 Co-Pay You car ns on page 3. checkir amay be made Iag my behalf. an	n get additional one-on- ig the box below. gree to receive marketir d texts made with an au	COSENTYX® CONNECT PATIE one support, such as recurring re ng calls and texts from and on beh todialer or prerecorded voice, at t d and is not a condition of receiving	minders, tips, and alf of Novartis and he phone number	d its affiliates, including calls r(s) I provide. I understand that
benefit insurance as applica	nt and back) of the patie able.		armacy insurance card(s). In harmacy 🗌 Patient Is Unir		secondary, and pharmacy
4 Provider Information		_ ·			
First Name*	Last Name*		Practice Name*		
Address			Practice Phone Number		
City	State	ZIP*	Office Contact Name		Office Contact Phone
Provider NPI Number*			Office Fax*		
Tax ID Number* (Required to run benefits for IV pa	PTAN Number tients)		Office Email		
	d Fax 4-666-1366 or 1-800-34	3-9117	Enroll Online www.CoverMyMeds.com		stions? Call 14-267-3689
U NOVARTIS	Complete the entire form	and fax to COSENTYX	s of patient medical records. © Connect Patient Support at 1-8 y delay the start of treatment.	44-666-1366.	9/24 FA-11269831 1

(For Office Use Only) Indicate your office's preferred level of engagement from Novartis Patient Support for this patient:*

Intravenous use — includes (select one):

Coverage, Prior Authorization, and Appeals Support:

Coverage, Prior Authorization, and Appeals Support:

START FORM

Subcutaneous use — includes:

09.2024 UPDATE

START FORM 09.2024 UPDATE	1							
* = REQUIRED FIELDS	5	Patient Name*	E	Date of Birt	th (MM/DD/YY	YY)*		(secukinumab)
5 Treating Site Information* (IV formulation use only) If you intend to send your patient to another site to receive COSENTYX® (secukinumab) IV formulation, please complete the information below. Please indicate your preferred alternate site, if any: Non-Prescribing MD's Office Hospital Outpatient Facility Home Infusion/Infusion Provider Company Other If alternate site of service is known, please fill out the details below:								
Site Name*				Expected	COSENTYX Trea	atment Date (MM/DD/	/ (YYYY)	
Address*				Phone				
City	State	ZIP*		Fax*				
Site NPI Number*	Tax ID Nu	umber*		Contact N	ame	Contac	ct Phone	
Primary Diagnosis/ICD-10-CM Codes (check one): L 40.0 Plaque Psoriasis L 40.5 Psoriatic Arthritis L 40.54 Psoriatic Juvenile Arthropathy L 73.2 Hidradenitis Suppurativa M08.90 Juvenile Arthritis, unspecified M45.0 Ankylosing Spondylitis M45.A Non-Radiographic Axial Spondyloarthritis Other ICD-10-CM Code(s):								
7 Prescription Infor	mation (for subcutar	neous use only)*				_		
Covered Until You're Covered Free Medication Prescription Ship first dose to: Patient Office, as allowable by law <u>All subsequent doses will be shipped to the patient</u> . HCP Preferred Specialty Pharmacy (optional):								
Pharmacy Prescript	tion and Covered	Until You're Cove						
Adult				ty 28 Days)	t 150 mg ou boutou	a a wake on Weake O 1		efills
COSENTYX 150 mg Sensoready® Pen (1x150 mg/mL)	Prefilled Syringe (1x150 mg/mL)				150 mg subcutan	neously on Weeks 0, 1, eously on Week 4, the		I/A] 12 refills, or refills
	Sensoready® Pen (2x150 mg/mL)	□Prefilled Syringe (2x150 mg/mL)			300 mg subcutar	neously on Weeks 0, 1 neously on Week 4, the		I/A] 12 refills, or refills
(1x300 mg/2 mL)			every 2 v	weeks (For pa	ase (HS only): Inje atients currently t Loading dose alre	ect 300 mg subcutane aking COSENTYX eve eady completed.)	eously ery	12 refills, or refills
Pediatric			Dosing (Qt	ty 28 Days)			R	efills
COSENTYX 75 mg (wt <50 kg)	□ Prefilled Syringe (1x75 mg/mL)				75 mg subcutane	eously on Weeks 0, 1, 2 ously on Week 4, then		I/A] 12 refills, or refills
COSENTYX 150 mg (wt ≥50 kg)	Sensoready® Pen (1x150 mg/mL)	Prefilled Syringe (1x150 mg/mL)			150 mg subcutan	neously on Weeks 0, 1, eously on Week 4, the		I/A] 12 refills, or refills

Provider Attestation

Prescriber must authorize these instructions by signing at the end of this section.

I certify the above therapy is medically necessary and this information is accurate to the best of my knowledge. I certify I am the provider who has prescribed COSENTYX to the previously identified patient and I provided the patient with a description of COSENTYX® Connect Patient Support. For the purposes of transmitting these prescriptions, I authorize NPAF, Novartis Pharmaceuticals Corporation, and its affiliates, business partners, and agents to forward as my agent, for these limited purposes, the prescriptions electronically, by facsimile, or by mail to the appropriate dispensing pharmacies. I will not attempt to seek reimbursement for free product provided to my office. I have discussed COSENTYX* Connect Patient Support with my patient, who has authorized me under HIPAA and state law to disclose their information to Novartis for the limited purpose of enrolling in COSENTYX* Connect Patient Support. To complete this enrollment, Novartis may contact the patient by phone, text, and/or email.

\rightarrow	X			
Provider Signature (Dispense as Written)* ATTN: Please follow your state's prescribing guidelines		(Substitution Permissible) s for electronic prescriptions (if applicable)	Provider Name (Print Name)	Date (MM/DD/YYYY)*
	Send Fax 1-844-666-1366 or 1-800-3	343-9117 Enroll Online www.CoverM		uestions? Call •844-267-3689
		not fax/submit any copies of patient me orm and fax to COSENTYX® Connect Patie		6.

An incomplete Start Form may delay the start of treatment.

UNOVARTIS

START FORM 09.2024 UPDATE



Patient Authorization

I authorize my healthcare providers, pharmacies and health insurers, and their service providers ("Providers") to disclose information relating to my insurance benefits, medical condition, treatment, and prescription details ("Personal Information") to Novartis Pharmaceuticals Corporation, its affiliates and service providers ("Novartis") and the Novartis Patient Assistance Foundation, Inc., and its service providers ("NPAF") so they can provide the following support services (the "Services"):

- Help coordinate insurance coverage for access to and receipt of my medication.
- Communicate with me about possible financial assistance, including Novartis co-pay or NPAF programs, and, if I am enrolled, administer my participation in those programs.
- Communicate with me about my medication and treatment, including reminders, health and lifestyle tips, and product and other related information. Communications may be customized based on Personal Information obtained from my Providers.
- Conduct quality assurance and other internal business activities and ask for feedback related to the Services or my treatment.

In delivering the Services, Novartis and NPAF may share my Personal Information with each other, with my Providers, or with government agencies or other financial assistance programs that might help me pay for my medication. They may combine information collected from me with information collected from other sources and use that information to administer the Services. My pharmacies or other healthcare providers may receive payment from Novartis or NPAF for providing certain Services, such as medication or refill reminders, based on my enrollment or participation. Once I authorize disclosure of my Personal Information, it may no longer be protected by federal health privacy law and applicable state laws.

I understand I do not have to sign this Authorization to get my medication or insurance coverage, that I have a right to a copy, and can cancel this Authorization at any time by calling 1-844-267-3689 or by writing to:

Customer Interaction Center Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, NJ 07936-1080

This Authorization will expire 5 years after I sign it, or earlier if required by state law, unless I cancel it sooner. If I cancel it, I may no longer qualify for Services from Novartis or NPAF, but it will not impact my Provider's treatment or my insurance benefits. I also understand that if a Provider is disclosing my Personal Information to Novartis or NPAF on an authorized, ongoing basis, my cancellation will be effective with respect to that Provider as soon as they receive notice of my cancellation. Cancellation will not affect prior uses or disclosures.

COSENTYX® Connect Co-Pay Offer Terms & Conditions

Limitations apply. Valid only for those with private insurance. Program provides up to \$16,000 annually for the cost of COSENTYX and up to \$150 per infusion (up to \$1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state healthcare program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or healthcare savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the US and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

*The Covered Until You're Covered Program is available for COSENTYX® (secukinumab) subcutaneous injection only. Eligible patients must have commercial insurance, a valid prescription for COSENTYX, and a denial of insurance coverage based on a prior authorization request. Program requires the submission of an appeal of the coverage denial within the first 90 days of enrollment in order to remain eligible. Program provides COSENTYX for free to eligible patients for up to two years, or until they receive insurance coverage approval, whichever occurs earlier. A valid prescription consistent with FDA-approved labeling is required. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. Enrolled patients awaiting coverage for COSENTYX after two years may be eligible for a limited Program extension. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

'Novartis Patient Support may call and text you at the numbers provided for non-marketing purposes (e.g., to help you access and start on COSENTYX). Calls may be autodialed or prerecorded. Message and data rates may apply. You may change your communication preferences at any time by calling 1-844-267-3689.

UNOVARTIS

Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080

FA-11269831

З